​

Xenon Pharmaceuticals (XENE) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

XENE Stock Forecast

Xenon Pharmaceuticals (XENE) stock forecast, based on 22 Wall Street analysts, predicts a 12-month average price target of $76.67, with a high of $100.00 and a low of $44.00. This represents a 29.86% increase from the last price of $59.04.

$35 $48 $61 $74 $87 $100 High: $100 Avg: $76.67 Low: $44 Last Closed Price: $59.04

XENE Stock Rating

Xenon Pharmaceuticals stock's rating consensus is Buy, based on 22 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 22 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 22 0 22 Strong Sell Sell Hold Buy Strong Buy

XENE Price Target Upside V Benchmarks

TypeNameUpside
StockXenon Pharmaceuticals29.86%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts7811
Avg Price Target$85.43$83.00$74.64
Last Closing Price$59.04$59.04$59.04
Upside/Downside44.70%40.58%26.42%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 26318---21
Feb, 26317---20
Jan, 26317---20
Dec, 25317---20
Nov, 25416---20
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 09, 2026Andrew TsaiJefferies$100.00$62.7659.34%69.38%
Mar 09, 2026Yatin SunejaGuggenheim$90.00$62.7643.40%52.44%
Mar 09, 2026Morgan Stanley$97.00$62.7654.56%64.30%
Mar 09, 2026Paul MatteisStifel Nicolaus$89.00$61.5844.53%50.75%
Mar 09, 2026Andrew TsaiJefferies$65.00$61.565.59%10.09%
Feb 23, 2026Wolfe Research$60.00$42.7240.45%1.63%
Feb 10, 2026Stifel Nicolaus$66.00$42.4355.55%11.79%
Nov 04, 2025RBC Capital$58.00$39.6346.35%-1.76%
Nov 04, 2025Josh SchimmerCantor Fitzgerald$55.00$39.7838.26%-6.84%
Nov 04, 2025Benjamin BurnettWells Fargo$44.00$41.127.00%-25.47%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 09, 2026GuggenheimBuyBuyhold
Mar 09, 2026Bank of America SecuritiesBuyBuyhold
Mar 09, 2026JefferiesBuyBuyhold
Feb 23, 2026Wolfe ResearchOutperforminitialise
Dec 26, 2025JefferiesBuyBuyhold
Nov 04, 2025RBC CapitalOutperformOutperformhold
Nov 04, 2025Cantor FitzgeraldOverweightOverweighthold
Nov 04, 2025Wells FargoOverweightOverweighthold
May 13, 2025RBC CapitalOutperformOutperformhold
May 13, 2025Wells FargoOverweightOverweighthold

Financial Forecast

EPS Forecast

$-5 $-4 $-3 $-2 $-1 $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.77$-2.06$-2.73$-3.01$-4.36---
Avg Forecast$-1.66$-2.09$-2.83$-3.10$-3.73$-4.10$-3.13$-0.08
High Forecast$-1.66$-2.09$-2.64$-2.97$-2.41$-2.88$-2.07$-0.08
Low Forecast$-1.66$-2.09$-2.91$-3.42$-4.32$-4.82$-4.60$-0.08
Surprise %6.63%-1.44%-3.53%-2.90%16.89%---

Revenue Forecast

$0 $110M $220M $330M $440M $550M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$18.44M$9.43M--$7.50M---
Avg Forecast$20.72M$12.16M$2.20M$333.33K$5.67M$37.09M$198.24M$518.49M
High Forecast$20.72M$12.16M$2.20M$333.33K$5.67M$37.09M$204.65M$518.49M
Low Forecast$20.72M$12.16M$2.20M$333.33K$5.67M$37.09M$191.83M$518.49M
Surprise %-11.02%-22.42%--32.35%---

Net Income Forecast

$-350M $-280M $-210M $-140M $-70M $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-78.88M$-125.37M$-182.39M$-234.33M$-345.91M---
Avg Forecast$-110.90M$-139.53M$-182.39M$-213.39M$-224.96M$-257.77M$-289.03M$-5.09M
High Forecast$-110.90M$-139.53M$-176.35M$-198.99M$-161.12M$-192.93M$-138.57M$-5.09M
Low Forecast$-110.90M$-139.53M$-194.45M$-228.83M$-288.81M$-322.62M$-307.51M$-5.09M
Surprise %-28.87%-10.14%-9.81%53.76%---

XENE Forecast FAQ

Is Xenon Pharmaceuticals stock a buy?

Xenon Pharmaceuticals stock has a consensus rating of Buy, based on 22 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 22 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Xenon Pharmaceuticals is a favorable investment for most analysts.

What is Xenon Pharmaceuticals's price target?

Xenon Pharmaceuticals's price target, set by 22 Wall Street analysts, averages $76.67 over the next 12 months. The price target range spans from $44 at the low end to $100 at the high end, suggesting a potential 29.86% change from the previous closing price of $59.04.

How does Xenon Pharmaceuticals stock forecast compare to its benchmarks?

Xenon Pharmaceuticals's stock forecast shows a 29.86% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Xenon Pharmaceuticals over the past three months?

  • March 2026: 14.29% Strong Buy, 85.71% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 15.00% Strong Buy, 85.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 15.00% Strong Buy, 85.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Xenon Pharmaceuticals’s EPS forecast?

Xenon Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2026 is $-4.1, marking a -5.96% decrease from the reported $-4.36 in 2025. Estimates for the following years are $-3.13 in 2027, and $-0.08 in 2028.

What is Xenon Pharmaceuticals’s revenue forecast?

Xenon Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2026 is $37.09M, reflecting a 394.53% increase from the reported $7.5M in 2025. The forecast for 2027 is $198.24M, and $518.49M for 2028.

What is Xenon Pharmaceuticals’s net income forecast?

Xenon Pharmaceuticals's net income forecast for the fiscal year ending in December 2026 stands at $-258M, representing a -25.48% decrease from the reported $-346M in 2025. Projections indicate $-289M in 2027, and $-5.092M in 2028.